30
Participants
Start Date
May 28, 2015
Primary Completion Date
October 8, 2020
Study Completion Date
October 8, 2020
Pembrolizumab
Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
mFOLFOX6
"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~* Oxaliplatin 85 mg/m\^2 IV with~* Leucovorin 400 mg/m\^2 IV followed by~* 5FU 400 mg/m\^2 bolus and then 2400 mg/m\^2 via continuous infusion"
Emory University: Winship Cancer Institute, Atlanta
The Ohio State University Comprehensive Cancer Center, Columbus
Indiana University Simon Cancer Center, Indianapolis
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Hoosier Cancer Research Network
OTHER